Si-Yang Maggie Liu

Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201).

Xue-Ning Yang, W. Zhong, S. Dong, 2023, Clinical lung cancer.

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial

Yi-long Wu, Jin-Ji Yang, Chongrui Xu, 2023, EClinicalMedicine.

Drug development and evidence for lung cancer targeted therapy in Eastern Asia

H. Horinouchi, Si-Yang Maggie Liu, Jia-Yi Deng, 2024, The Lancet Regional Health - Western Pacific.

PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial.

Jin-Ji Yang, Chongrui Xu, Xuchao Zhang, 2023, Science bulletin.